RRD-251
RRD-251 is an inhibitor of retinoblastoma tumor suppressor protein (Rb) -Raf-1 interaction, with potent anti-proliferative, anti-angiogenic and anti-tumor activities[1].
Product Specifications
CAS Number
[72214-67-6]
Product Name Alternative
SR1378,7-Deazaadenosine
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Raf
Type
Reference compound
Related Pathways
Apoptosis; MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/rrd-251.html
Concentration
10mM
Purity
99.87
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
NC(SCC1=CC=C(Cl)C=C1Cl)=N.[H]Cl
Molecular Formula
C8H9Cl3N2S
Molecular Weight
271.59
Precautions
H302, H315, H319, H335
References & Citations
[1]Sandeep Singh, et al. Rb-Raf-1 interaction disruptor RRD-251 induces apoptosis in metastatic melanoma cells and synergizes with dacarbazine. Mol Cancer Ther. 2010 Dec; 9 (12) : 3330–3341.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6491618-01 0.2 mL
EP300, Phosphorylated (Ser89) (Histone Acetyltransferase p300, E1A-associated Protein p300, p300 HAT) (Azide free) (HRP)
Ask
View Details MBS6491618-02 5x 0.2 mL
EP300, Phosphorylated (Ser89) (Histone Acetyltransferase p300, E1A-associated Protein p300, p300 HAT) (Azide free) (HRP)
Ask
View Details bsm-41267M-Cy5-01 20 µL
SARS-CoV-2 (2019-nCoV) Nucleocapsid (1G4) Monoclonal Antibody, Cy5 Conjugated
Ask
View Details 
bsm-41267M-Cy5-02 100 µL
SARS-CoV-2 (2019-nCoV) Nucleocapsid (1G4) Monoclonal Antibody, Cy5 Conjugated
Ask
View Details 